Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Milveterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 19/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 5/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Milveterol SCHEMBL168972 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL265695 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL4385046 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL265694 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL29448200 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL2953766 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL2953771 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL2014102 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL2014100 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL2014099 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108026080-B | Pyrazolyl-substituted heteroaryl compounds and their use as medicaments | 勃林格殷格翰国际有限公司 | 2021-06-11 | — | — | CN | disclosed |
| US-10947243-B2 | Heteroaryl SYK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| EP-3347353-B1 | PYRAZOLYL-SUBSTITUTED HETEROARYLS AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2019-07-17 | — | — | EP | disclosed |
| EP-3119765-B1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-07-17 | — | — | EP | disclosed |
| EP-3119766-B1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-05-22 | — | — | EP | disclosed |
| EP-3119772-B1 | HETEROARYL SIK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-05-22 | — | — | EP | disclosed |
| US-10155751-B2 | Pyrazolyl-substituted heteroaryls and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-12-18 | — | — | US | disclosed |
| EP-3347353-A1 | PYRAZOLYL-SUBSTITUTED HETEROARYLS AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2018-07-18 | — | — | EP | disclosed |
| US-20180148433-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | BOEHRINGER INGELHEIM INT (DE) | 2018-05-31 | — | — | US | disclosed |
| US-20180072744-A1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-15 | — | — | US | disclosed |
| WO-2011098607-A1 | SALTS AND HYDRATES OF 4-[(3-CHLOR-4-FLUORO-PHENYL)AMINO]-6-(CIS-4-{N-[(MORPH-1-OLINO-4-YL)CARBONYL]-N-METHYL-AMINO}-CYCLOHEXANE-1-YLOXY)-7-METHOXY-QUINAZOLINE, THEIR USE AS DRUGS AND THEIR PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011092128-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |
| EP-2313398-A1 | CYCLOHEXYLOXY-SUBSTITUTED HETEROCYCLICS, MEDICINES CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF | Boehringer Ingelheim International GmbH (DE) | 2011-04-27 | — | — | EP | disclosed |
| EP-2313397-A1 | CYCLOHEXYLOXY-SUBSTITUTED HETEROCYCLICS, MEDICINES CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF | Boehringer Ingelheim International GmbH (DE) | 2011-04-27 | — | — | EP | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| WO-2010097372-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010097373-A1 | COMPOUNDS FOR USE AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010097374-A1 | COMPOUNDS FOR USE AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010015522-A1 | CYCLOHEXYLOXY-SUBSTITUTED HETEROCYCLICS, MEDICINES CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010015523-A1 | CYCLOHEXYLOXY-SUBSTITUTED HETEROCYCLICS, MEDICINES CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155751-B2 | Pyrazolyl-substituted heteroaryls and their use as medicaments | HRH4, HRH3, HRH1 | ADRB2 55/4885ADRB1 58/4885ADRB3 20/4885 |
| US-10947243-B2 | Heteroaryl SYK inhibitors | SYK, BTK, CD40 | ADRB2 1410/4885ADRB1 887/4885ADRB3 1216/4885 |
| US-20180148433-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | HRH4, HRH2, HRH3 | ADRB2 50/4885ADRB1 80/4885ADRB3 24/4885 |
| US-20180072744-A1 | HETEROARYL SYK INHIBITORS | SYK, BTK, CD40 | ADRB2 1410/4885ADRB1 887/4885ADRB3 1216/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | ADRB2 484/4885ADRB1 275/4885ADRB3 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.